UD Standard Web Header

Scott A. Waldman

Vice President, Clinical and Translational Research, Thomas Jefferson University
Associate Dean, Clinical and Translational Sciences, Jefferson Medical College
Chair, Department of Pharmacology and Experimental Therapeutics Samuel MV Hamilton Endowed Professor
Director, GI Malignancies Program, Kimmel Cancer Center

Departments of Pharmacology and Experimental Therapeutics and Medicine
Thomas Jefferson University
132 South 10th Street
1170 Main
Philadelphia, Pennsylvania 19107
(215)955-5682
scott.waldman@jefferson.edu

Education/Certification

  • Stanford University, Palo Alto, California
    School of Medicine: 1983-1987
    M.D. conferred June, 1987
  • Thomas Jefferson University, Philadelphia, Pennsylvania
    Department of Anatomy, School of Medicine: 1975-1979
    Ph.D. conferred June, 1980
    Majors: Human Anatomy, Biochemistry
    Minor: Developmental Biology
  • State University of New York at Albany, Albany, New York: 1971-1975
    B.S. conferred May, 1975
    Major: Biology
    Minor: Chemistry
  • Clinical Training

  • 1988-1990 Resident, Department of Medicine, Stanford University Hospital, Palo Alto, California.
  • 1987-1988 Intern, Department of Medicine, Stanford University Hospital, Palo Alto, California.

Professional Experience

    Faculty Appointments
    Thomas Jefferson University, Philadelphia, Pennsylvania:

  • 2010-present Vice President, Clinical and Translational Research, Thomas Jefferson University.
  • 2010-present Associate Dean, Clinical and Translational Sciences, Jefferson Medical College.
  • 2005-present Chair, Department of Pharmacology and Experimental Therapeutics.
  • 2000-present Professor of Biochemistry and Molecular Pharmacology.
  • 1999-present Tenure granted.
  • 1998-present Samuel M.V. Hamilton Professor of Medicine.
  • 1997-present Director, Division of Clinical Pharmacology.
  • 1996-1997 Associate Director of Clinical Trials, Office of Scientific Affairs.
  • 1993-1998 Associate Professor of Medicine, Division of Clinical Pharmacology.
  • 1993-1998 Associate Professor of Biochemistry and Molecular Pharmacology.
  • 1991-present Graduate Faculty.
  • 1990-1993 Assistant Professor of Medicine, Division of Clinical Pharmacology.
  • 1990-1993 Assistant Professor of Pharmacology.
  • Veterans Administration Medical Center, Palo Alto, California:

  • 1983-1990 Staff Pharmacologist.
  • Clinical Appointments

  • 1991-present Attending Physician, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
  • 1991-1997 Medical Director, Clinical Research Unit, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Recent Publications/Books & Publications

  • Zuzga, D.S., Pelta-Heller, J., Li, P., Bombonati, A., Waldman, S.A., and Pitari, G.M. (2011) VASP Ser239 phosphorylation is an invasion suppressor mechanism in colon cancer. (Submitted).
  • Snook, A.E., Magee, M.S., Marszalowicz, G.P, Schulz, S., and Waldman, S.A. (2011) Immunization against the mucosal autoantigen, guanylyl cyclase C induces high-affinity cytotoxic T cells with anti-tumor efficacy. (Submitted).
  • Crist, R.C., Roth, J.J., Waldman, S.A., Siracusa, L.D., and Buchberg, A.M. (2011) A conserved homeodomain-less isoform of MEIS1 is downregulated in colorectal cancer. (Submitted).
  • Waldman, S.A. and Terzic, A. (2009) Pharmacology And Therapeutics: Principles To Practice. Elsevier, Philadelphia.
  • Waldman, S.A. and Terzic, A. (2009) Pharmacotherapeutic continuum: Engineering the future of clinical medicine. Pharmacology And Therapeutics: Principles To Practice. (S.A. Waldman, A. Terzic, eds.) pp. 3-5, Elsevier, Philadelphia.
  • Waldman, S.A. and Terzic, A. (2009) Drug-receptor interactions. Pharmacology And Therapeutics: Principles To Practice. (S.A. Waldman, A. Terzic, eds.) pp. 51-65, Elsevier, Philadelphia.

Grants

  • 07/10-06/15 NIH T32 GM08562-16, Postdoctoral training program in clinical pharmacology: Supplement in Pediatric Clinical Pharmacology; P.I., S.A. Waldman, M.D., Ph.D., $80,000.
  • 07/10-06/15 NIH T32 GM08562-16, Postdoctoral training program in clinical pharmacology; P.I., S.A. Waldman, M.D., Ph.D., $250,000.
  • 06/10-05/14 Commonwealth Universal Research Enhancement (CURE), P.I., Scott A. Waldman, Program Project Center of Excellence for Cancer Immunotherapy, P.I., S.A. Waldman, M.D., Ph.D; 06/10-05/14; $1,100,000 (Pennsylvania Tobacco Non-Formula Funds).
  • 01/10-12/11 PhRMA Foundation Postdoctoral Fellowship Award for Francheska Colon-Gonzalez, Ph.D., $40,000.
  • 10/01-09/11 NIH RC1 CA146033 Occult lymph node metastases and racial disparities in colon cancer outcomes, P.I., S.A. Waldman, M.D., Ph.D; 10/09-09/11; $500,000 (Challenge Grant).
  • 05/10-04/11 Veterans Administration, Statistical Designs for Marker Validation Studies in Treatment, P.I., A. Zhou, Ph.D., Co-I, P.I., S.A. Waldman, M.D., Ph.D.; $200,000.
  • 01/09-12/10 Elsa Pardee, Selective targeting of colorectal cancer cells, P.I., Chang Chang, Ph.D., Co-PI, S.A. Waldman, M.D., Ph.D., $101,811.
  • 06/08-05/13 NCI 5 P30 CA56036, Translational Research Center (Institutional Cancer Center Core Grant), P.I., R. Pestell, M.D., S.A. Waldman, M.D., Ph.D., Gastrointestinal Cancer Program Leader.
  • 11/05-06/11 NIH R21-R33 CA112147, Nonlinear models and mRNA expression of biomarkers by Q-RT-PCR, P.I., T. Hyslop, Ph.D., Co-I, S.A. Waldman, M.D., Ph.D.; $100,000.
  • 07/03-05/11 NIH R01 CA95026, Colorectal cancer and guanylyl cyclase C in blood, P.I., S.A. Waldman, M.D., Ph.D; 06/03-05/08; $782,608.
  • 1994-2012 Targeted Diagnostics and Therapeutics, Inc. E. coli heat-stable enterotoxin for targeting diagnostics and therapeutics to colorectal cancer; P.I., S.A. Waldman, M.D., Ph.D.; 11/1/02-10/31/06; $250,000.
  • 1975-2013 Merck Research Laboratories, Collaborative Program in Clinical Pharmacology; P.I., S.A. Waldman, M.D., Ph.D. (since 1996), $1,200,000.

Honors & Awards

  • 2011 PhRMA Foundation Award in Excellence in Clinical Pharmacology
  • 2010 Henry Elliott Award, American Society for Clinical Pharmacology and Therapeutics
  • 2007-present Editorial Board Member, Personalized Medicine
  • 2007-present Editorial Board Member, Expert Reviews In Clinical Pharmacology
  • 2007-present Editorial Board Member, Drug Design, Development and Therapy
  • 2007-present Editorial Board Member, Regenerative Medicine
  • 2007-present Editorial Board, Open Pharmacology
  • 2007-present Inaugural Deputy Editor, Clinical And Translational Science
  • 2006-present Inaugural Senior Editor, Biomarkers In Medicine
  • 2006-present Editorial Board Member, World Journal Of Gastroenterology
  • 2006-present Editor-In-Chief, Clinical Pharmacology & Therapeutics.
  • 2006-present Chair, NCI Initial Review Group Subcommittee J.
  • 2005-2006 Co-Chair, NCI Initial Review Group Subcommittee J.
  • 2005-present Chair, Department of Pharmacology and Experimental Therapeutics.
  • 2004 Interurban Clinical Club (Osler Society).
  • 2004 Chair, NIGMS Special Emphasis Panel ZRG1 GGG-B (50), Pharmacogenomics Research Network, December 14-15, Bethesda, MD.
  • 2004 Visiting Professor, Lankenau Research Institute, Wynnewood, PA, November 4, 2004.
  • 2004-present College of Reviewers for the Canada Research Chairs Program.
  • 2004 Keynote Speaker, Mauvernay Symposium, Tulane University, New Orleans (10/08/04).
  • 2004, 2005 Judge, Mauvernay Research Excellence Award.
  • 2004 Visiting Professor, Louisiana Cancer Research Consortium Visiting Professor, Louisiana State and Tulane Universities, New Orleans, Louisiana, July 14-16, 2004.
  • 2004-present Editorial Board Member, Therapeutics and Clinical Risk Management.
  • 2004-2005 Co-Chair, NCI Initial Review Group Subcommittee G.
  • 2004-present Council of Clinical Pharmacology.
  • 2004 Dean’s Citation for Faculty Mentoring, Thomas Jefferson University.
  • 2004 Editorial Board Member, Physicians OnLine.
  • 2003-present Editorial Board Member, Biotechnology Healthcare.
  • 2003-2007 Editorial Board Member, Cancer Therapeutics.
  • 2003 Review panel, Kogod Awards, Mayo Clinic and Foundation 11/20/03.
  • August 2003 AHRQ Special Emphasis Panel for CERTs review.
  • April 2003 McEwen Lecturer, Queens University, Kingston, Ontario, Canada.
  • 12/02 Co-Chair, International Advisory Committee on the Development of Fasudil, 12/06/02-12/08/02, New York, New York.
  • 2002-2003 Past President of the American Society for Clinical Pharmacology and Therapeutics.
  • 01/07-08/02 Invited participant, NCI Workshop on Detection and Measurement of Occult Disease.
  • 09/01-present Member of the NIH Study Section NCI-G M1 P.
  • 2001 Strategic Planning Steering Committee of Thomas Jefferson University.
  • 06/01 NIH Study Section. ZGM1 BRT-2 (ad hoc).
  • 2001-2002 President of the American Society for Clinical Pharmacology and Therapeutics.
  • 02/01 Chair, Tumor Markers, The Molecular Medicine of Colorectal Cancer; Keystone Symposia on Molecular and Cellular Biology. Taos, New Mexico, January 30-February 4, 2001.
  • 2000 Member, Advisory Committee of the Graduate Center in the College of Graduate Studies, Thomas Jefferson University.
  • 2000-2001 President Elect of the American Society for Clinical Pharmacology and Therapeutics.
  • 2000-2004 Secretary, American Board of Clinical Pharmacology.
  • 3/00, 2/01 NIH Study Section. NCI-G M1 P (ad hoc).
  • 1/00 NIH Colorectal Cancer Roundtable Meeting, San Francisco, January 5-7, 2000.
  • 12/99 Visiting Faculty, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA.
  • 12/99 Visiting Professor, Section on Clinical Pharmacology, University of Chicago, Chicago, IL.
  • 11/99 NIH Special Emphasis Panel ZRG1 ALTX4 B Study Section Member.
  • 11/99 Visiting Professor, Department of Pharmacology, University of Catania, Catania, Italy.
  • 1999-2003 Member of the Clinical Pharmacology Executive Committee, American Society for Pharmacology and Therapeutics.
  • 1999-2004 Elected Regent of the American College of Clinical Pharmacology.
  • 1999 Tenure granted.
  • 8/99 Visiting Faculty, Department of Pharmacology, Georgetown University School of Medicine, Washington, D.C.
  • 7/99 NIH Agency for Health Care Policy and Research Special Emphasis Panel.
  • 1999 NIH GMA2 Study Section (ad hoc).
  • 1999-2000 Vice President, American Society for Clinical Pharmacology and Therapeutics.
  • 1998 Promoted to Professor, Department of Medicine.
  • 1998 Invited participant, Nobel Lectures and Symposia, Stockholm, Sweden.
  • 1998-present Member, American Board of Clinical Pharmacology.
  • 1998-1999 Re-elected Chairman, Molecular Therapeutics Section, American Society for Clinical Pharmacology and Therapeutics.
  • 3/98 Nominating Committee, American Society for Clinical Pharmacology and Therapeutics.
  • 3/98 Visiting Faculty, Clinical Pharmacology Unit, Mayo Clinic, Rochester, MN.
  • 1/98 Invited participant, Strategic Planning Retreat, American Society for Clinical Pharmacology and Therapeutics.
  • 1997-present Member, Kimmel Cancer Institute, Thomas Jefferson University.
  • 1997-2000 Scientific Program Committee, American Society for Clinical Pharmacology and Therapeutics.
  • 1997-present Samuel M.V. Hamilton Professor in Medicine.
  • 1997-present Director, Division of Clinical Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • 1996-1997 Associate Director of Clinical Trials, Office of Scientific Affairs, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • 1996-1997 Acting Director, Division of Clinical Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • 1995-present Member, Finance Committee, American College of Clinical Pharmacology.
  • 1995-1999 Chairman, Molecular Therapeutics Section, American Society for Clinical Pharmacology and Therapeutics (Re-elected 1998).
  • 1995-2003 Board of Directors, American Society for Clinical Pharmacology and Therapeutics (Re-elected 1998).
  • 1994-present Fellow of the American College of Clinical Pharmacology.
  • 1994-present Editorial Board, Journal of Clinical Pharmacology.
  • 1994 NIH Clinical Sciences II Study Section.
  • 1993-1994 Vice-Chairman, Molecular Therapeutics Section, American Society for Clinical Pharmacology and Therapeutics.
  • 1991-1993 Pharmaceutical Manufacturers’ Association Faculty Development Award in Basic Pharmacology.
  • 1987 Stanford University Award for Distinguished Research In Clinical Pharmacology as a medical student.
  • 1987 Elected to the American Association For Clinical Chemistry Speakers Bureau.
  • 1987, 1988 Veterans Administration Award for Superior Performance.
  • 1980-1982 NIH Postdoctoral Fellow.
  • 1976-1979 NIH Predoctoral Fellow.
  • 1975-1976 Thomas Jefferson University Graduate School Fellow.
  • 1975 Bachelor of Science, Magna Cum Laude.
  • 1975 New York Regents' Scholarship for graduate education.
  • 1971-1975 New York Regents' Scholarship for undergraduate education.

Professional Membership

  • American Association for the Advancement of Science
  • American Association for Cancer Research
  • American College of Clinical Pharmacology
    Fellow (1994-present)
    Editorial Board, Journal of Clinical Pharmacology (1994-present)
    Finance Committee (1995-2004)
    Regent (1999-2004)
  • American College of Physicians
  • American College of Surgeons Oncology Group
  • American Federation for Clinical Research
  • American Medical Association
  • American Society for Biochemistry and Molecular Biology
  • American Society for Cell Biology
  • American Society for Clinical Pharmacology and Therapeutics
    Vice-Chairman, Molecular Therapeutics Section (1992-1995)
    Chairman, Molecular Therapeutics Section (1995-1999)
    Committee on Coordination of Scientific Sections (1995-1999)
    Board of Directors (1995-2003)
    Scientific Programming Committee (1997-2001; 2003-present; Co-Chair 2003-2004; Chair 2004-2005)
    Nominating Committee (1997)
    Vice President (1999-2000)
    Chair, Governance Task Force (200-2001)
    President Elect (2000-2001)
    President (2001-2002)
    Past President (2002-2003)
    Chair, Strategic Planning Task Force (2002-2003)
  • Mid-Atlantic Pharmacology Society
  • Sigma Xi
  • American Society for Pharmacology and Experimental Therapeutics
    Clinical Pharmacology Executive Committee (1999-2003)

  • College of Health Sciences  •   345 McDowell Hall  •   Newark, DE 19716  •   USA
    Phone: 302-831-2381  •  © 2014
    Comments   |    Contact Us    |    Legal Notices